



UNIVERSITÉ  
DE GENÈVE

# PRESS RELEASE

Geneva | 1 March 2022



University of  
Zurich <sup>UZH</sup>

abbvie

**WARNING: embargoed until 1 March 2022, 16:00 GMT**


**Neurons in the brain coexist with and rely on many other cell types to function properly. Astrocytes, which take their name from their star shape, ensure the survival of neurons by feeding and detoxifying them with the help of a multifunctional protein, APOE. One of three forms of this protein, *APOE4*, significantly increases the risk of developing Alzheimer's disease, but the mechanisms at play are unknown. A collaboration between the University of Geneva (UNIGE), the European Molecular Biology Laboratory (EMBL), the University of Zurich and the pharmaceutical company AbbVie has discovered a potential mechanism: far from ceasing to function, *APOE4* is on the contrary more efficient. By triggering astrocytic lipid secretion, it causes the accumulation of potentially toxic lipids that are harmful to neurons, and thus might contribute to the development of Alzheimer's disease. These results published in the journal *Cell Reports*, shed new light on the neurodegenerative mechanisms of a disease that affects nearly 50 million people worldwide.**

## The role of lipids in the development of Alzheimer's disease

A European consortium coordinated by UNIGE shows how a mutation in the APOE protein changes the lipid transport in the brain and could promote the arise of Alzheimer's disease.

Astrocytes, present in very large numbers in the brain, have a major protective function. These cells secrete apolipoprotein E (or APOE), a small protein that forms particles containing lipids and vitamins to feed the neurons. It also detoxifies the neurons by getting them rid of "lipid waste" that could become harmful if not removed. As the neurons are unable to eliminate this waste on their own, APOE comes into play to collect it and bring it back to the astrocytes where it is destroyed.

The gene coding for APOE exists in three frequent variants in humans: *APOE2*, present in 8% of the population, *APOE3*, the most common, and *APOE4*, which is found in nearly 15% of people and increases the risk of developing Alzheimer's disease by a factor of ten. "The reasons why *APOE4* increases the risk of Alzheimer's disease so significantly are not well understood," explains Anne-Claude Gavin, a professor in the Department of Cell Physiology and Metabolism at the UNIGE Faculty of Medicine and holder of a Louis-Jeantet Foundation Chair, who directed this research together with Viktor Lakics, a Research fellow and Biology Area Leader in Neuroscience discovery at AbbVie. What are the mechanisms behind the dysfunction of *APOE4*? And above all, could they serve as a basis for prevention or therapy? To answer these questions, Anne-Claude Gavin and her team joined forces with scientists from the European Molecular Biology Laboratory (EMBL), the University of Zurich and AbbVie.



© UNIGE / Anne-Claude Gavin

An astrocyte that stores lipids in droplets (pink) and starts secreting toxic lipids in the surrounding tissue.

**High resolution pictures**

## contact

### Anne-Claude Gavin

Full Professor

Louis-Jeantet Chair

Department of Cell Physiology  
and Metabolism

Faculty Diabetes Centre

Faculty of Medicine

+41 22 379 52 08

Anne-Claude.Gavin@unige.ch

### Karina Lindner

PhD Student

Department of Cell Physiology  
and Metabolism

Faculty of Medicine

+41 22 379 52 07

Karina.Lindner@unige.ch

DOI: [10.1016/j.celrep.2022.110435](https://doi.org/10.1016/j.celrep.2022.110435)

### A protein that is too effective

Working on these questions, the research team identified novel molecular mechanisms that explain how APOE binds to astrocyte membranes to detect and extract the lipids it needs. Employing human cell lines with different APOE variants, *in vitro* experiments demonstrated that APOE is very efficient at transporting potentially harmful lipids produced in neurons. “And to our great surprise, the *APOE4* variant proved to be even more efficient than the other forms”, reveals Katharina Beckenbauer, a former post-doc in Anne-Claude Gavin’s group, senior scientist at AbbVie, and one of the first authors of the work. “So, contrary to what we thought until now, the problem is not that *APOE4* stops working, but, in fact, the opposite. And the mechanism goes haywire.”

### A hijacked function

As astrocytes age, they become less efficient and start to accumulate lipids rather than destroy them. “We modelled this process experimentally and observed the molecules secreted by the astrocytes,” explains Karina Lindner, a PhD student in Anne-Claude Gavin’s laboratory and one of the first authors of this work. “We observed that cellular ageing diverts APOE from its primary function — transporting lipids to neurons and also recovering lipid waste from them - towards the secretion of triglycerides, particular lipid species that could become harmful if not removed.” And this phenomenon is exacerbated with *APOE4*: it stimulates the secretion of triglycerides, leading to their uncontrolled accumulation. This deleterious accumulation of potentially harmful lipids could very well be an important contributor to the neuronal death, a hallmark of Alzheimer’s disease. “*APOE4* would thus have the capacity to accelerate the pathological process in the disease through the mechanism we have discovered.”

In order to better understand the details of the action of APOE and especially of the E4 variant, the scientists at UNIGE want now to determine how secretion of these potentially harmful lipids is regulated and whether this secretion can be detected in people suffering from Alzheimer’s disease.

**UNIVERSITÉ DE GENÈVE**  
**Communication Department**

24 rue du Général-Dufour  
CH-1211 Geneva 4

Tel. +41 22 379 77 17

[media@unige.ch](mailto:media@unige.ch)

[www.unige.ch](http://www.unige.ch)